LOG IN OR SIGN UP TO "MY Eu2P"PROJECT HISTORY [2009-2016]
The Eu2P training programme has been created thanks to the financial support of the Innovative Medicines Initiative (IMI), a joint undertaking between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA):
- 2009-2014 funding
The IMI call wanted to foster, via customised training programmes, a common understanding in benefits and risks of medicines, a proactive pharmacovigilance and risk management of medicines by professionals in pharmacovigilance from industry and regulatory agencies in the European Union and beyond.
IMI 1st Call 2008 - IMI Eu2P project page - 2014-2016 funding
A new collaborative education and training project (imi-train) brought an opportunity for Eu2P to create a new shorter training format, the Eu2P Short Courses, based on the Master and Certificate course modules' material, to target healthcare professionals with very limited time availability for on-the-job training... Eu2P also teamed up with the IMI SafeSciMET programme to develop two blended learning course pilots which online material is hosted, designed and accessed from within the Eu2P eLearning platform.
IMI ENSO Call - imi-train website
Work Packages
- WP1: Programme and course coordination
Co-led by Université de Bordeaux and Roche - WP2: Project management and communication
Co-led by Université de Bordeaux and AstraZeneca - WP3: Common training and communication tools
Co-led by Université de Bordeaux and Bayer Healthcare
- WP4: Benefit assessment of medicines
Co-led by Fundació Institut Català de Farmacologia, Barcelona and Roche - WP5: Regulatory aspects in the evaluation of medicines
Co-led by University of Hertfordshire and GlaxoSmithKline - WP6: Medicines risk identification and quantification
Co-led by Erasmus Universitair Medisch Centrum, Rotterdam and Sanofi-Aventis (and then Lundbeck) - WP7: Medicines benefit-risk assessment and management
Co-led by Universiteit Utrecht and Roche - WP8: Medicines and public health
Co-led by Fundació Institut Català de Farmacologia, Barcelona and Amgen - WP9: Medicines Risk communication
Co-led by Université de Bordeaux and Lilly
Public-Private Partnership Consortium
Universities, Research Organisations, Public Bodies & Non-Profit
- Université de Bordeaux
IMI Funding Managing Entity
Co-leader of WP1, WP2, WP3 and WP9 (with Università degli Studi di Verona) - Fundació Institut Català de Farmacologia, Universitat Autònoma de Barcelona
Co-leader of WP4, WP8 - University of Hertfordshire
Co-leader of WP5 - Erasmus Universitair Medisch Centrum, Rotterdam
Co-leader of WP6 - Universiteit Utrecht
Co-leader of WP7 - Università degli Studi di Verona
Co-leader of WP9 (with Université de Bordeaux) - Karolinska Institutet
Active collaboration in WP8
- European Medicines Agency
Active collaboration in WP5 - Agence Nationale de Sécurité du Médicament
Active collaboration in WP9
EFPIA
- Roche
IMI Project Coordinator
Co-leader of WP1, WP4, and WP7.
Active collaboration in WP2, WP6 and WP8 - AstraZeneca
Co-leader of WP2.
Active collaboration in WP9 - Bayer Healthcare
Co-leader of WP3.
Active collaboration in WP1 and WP2 - GlaxoSmithKline
Co-leader of WP5 - Sanofi
Co-leader of WP6 - AMGEN
Co-leader of WP8.
Active collaboration in WP4 - Lilly
Co-leader of WP9 - Lundbeck
Active collaboration in WP5 and WP7 - Novartis
Active collaboration in WP5 - Orion Pharma
Active collaboration in WP5 - UCB
Active collaboration in WP6 - Almirall
Active collaboration in WP7 - Janssen
Active collaboration in WP7 - Boehringer Ingelheim
- Novo Nordisk
: Members of the Steering Committee group.
